Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06742099

The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion

Outcome of Intercostal Tube Insertion and Pleurodesis for Malignant Pleural Effusion

Status
Not Yet Recruiting
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Approximately half of all patients with metastatic cancer develop a malignant pleural effusion which is likely to lead to a significant reduction in quality of life secondary to symptoms such as dyspnoea and cough. The aim of pleurodesis in these patients is to prevent re-accumulation of the effusion and thereby of symptoms,and avoid the need for repeated hospitalization for thoracocentesis. Numerous clinical studies have been performed to try to determine the optimal pleurodesis strategy, and synthesis of the available evidence should facilitate this. The treatment of MPE is aimed at palliating symptoms since no intervention has been shown to improve survival in this population and since survival is generally limited in cancers that have spread to the pleural space. In this palliative setting, only patients symptomatic from their MPE should be submitted to further intervention. As well, further interventions in symptomatic patients should be limited to those patients who have experienced symptomatic improvement following initial therapeutic thoracentesis. The two main treatment approaches to MPE are to obliterate the pleural space via a pleurodesis procedure or to chronically drain the pleural cavity with Intercostal tube. The aims of this review were to ascertain the optimal procedure in cases of malignant pleural effusion in terms of patients' quality of life post procedure, recurrence of effusion.

Conditions

Interventions

TypeNameDescription
PROCEDUREIntercostal chest tubethe use of chest tubes to drain malignant pleural effusion
COMBINATION_PRODUCTPleurodesisthe injection of Talc in pleural space to induce inflammation reaction and produce pleurodesis

Timeline

Start date
2024-12-30
Primary completion
2025-06-15
Completion
2025-09-30
First posted
2024-12-19
Last updated
2024-12-19

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06742099. Inclusion in this directory is not an endorsement.